Kailera Posts $95.7M Q3 Loss as Obesity Pipeline Hits Full Enrollment
KLRA sits 31% above its 52-week low of $9.76.
Summary
Kailera's Q3 net loss widened to $95.7 million from $39.6 million a year earlier, driven by R&D spending that jumped to $84.7 million from $27.0 million as the obesity pipeline scales. Cash, equivalents and marketable securities stood at $1.04 billion at September 30, which the company says funds operations into mid-2028. The quarter's operational news is enrollment: the ribupatide injection Phase 3 KaiNETIC program (~5,000 participants) and the Phase 2b high-dose trial (~260 participants) are both fully enrolled, with data expected mid-2028 and mid-2027 respectively. Kailera also completed an End-of-Phase 2 meeting with the FDA for oral ribupatide and now targets a Phase 3 start in the first half of 2027, while safiglipron Phase 2 data slipped to mid-2027. The cash position and milestone calendar are the substance here; the wider loss is the expected cost of running four programs at once.
At the time of this announcement, KLRA was trading at $12.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $9.76 to $28.23. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.